Article
Multidisciplinary Sciences
Nicola Mumoli, Francesco Dentali, Giulia Conte, Alessandra Colombo, Riccardo Capra, Cesare Porta, Giuseppe Rotiroti, Francesca Zuretti, Marco Cei, Flavio Tangianu, Isabella Evangelista, Jose Vitale, Antonino Mazzone, Igor Giarretta
Summary: This study investigated the incidence of upper extremity deep vein thrombosis (UEDVT) in patients with moderate to severe COVID-19 infection and found that patients requiring helmet continuous positive airway pressure (CPAP) ventilation were at higher risk of developing UEDVT, which was associated with increased mortality.
Article
Oncology
Taylor W. Butler, Nadeen T. Ali, Mateusz J. Spalek, Sara Scott, Nikolaos Tsoukalas
Summary: This review examines the available evidence for risk assessment and primary thromboprophylaxis for oncology patients hospitalized for acute medical illness. The results show that risk assessments for thrombosis are primarily based on studies conducted in the general population and there is a lack of specific risk assessment for oncology patients. Evidence for thromboprophylaxis in oncology patients is conflicting and mainly comes from sub-group analysis of larger studies in the general population. The strength of recommendations from international guidelines is limited due to the lack of sufficient evidence. Future research should focus on improving risk assessment and understanding the appropriate treatment for this patient population.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Pharmacology & Pharmacy
Hannah C. Puhr, Ayseguel Ilhan-Mutlu, Matthias Preusser, Peter Quehenberger, Paul A. Kyrle, Sabine Eichinger, Lisbeth Eischer
Summary: Direct oral anticoagulants (DOACs) are safe and effective in cancer patients treated for venous thromboembolism (VTE) or atrial fibrillation (AF) after gastrectomy. However, caution should be exercised when using dabigatran in this patient population due to the risk of recurrent thromboembolic events.
Article
Medicine, General & Internal
Hyung Jun Kim, Jong-Won Chung, Oh Young Bang, Yeon Hee Cho, Yun Jeong Lim, Jaechun Hwang, Woo-Keun Seo, Gyeong-Moon Kim, Hee-Jin Kim, Myung-Ju Ahn
Summary: The mechanisms of coagulopathy and the effects of anticoagulants were compared in patients with active cancer and atrial fibrillation (AF). The results showed that the anticoagulation effects of factor Xa inhibitors differed between cancer stroke and AF stroke patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Cuilian Weng, Xincai Wang, Long Huang, Xingsheng Lin, Qinghua Liu
Summary: In patients at intermediate-high risk of developing a pulmonary embolism, low-dose urokinase thrombolytic therapy may increase CTPA-confirmed absorption and improve short-term and long-term dyspnea without affecting mortality or increasing the risk of bleeding.
Review
Oncology
Tzu-Fei Wang, Marc Carrier
Summary: Immune checkpoint inhibitors have become an integral part of cancer treatment, but they carry the risk of thrombosis, which can lead to various complications. Recent studies have shown that C-reactive protein dynamics may serve as a biomarker for thrombosis. Furthermore, early findings suggest that factor Xa inhibitors used for cancer-associated thrombosis may have potential synergistic antitumor effects when combined with ICIs.
Article
Hematology
Nadia Abelhad, Wei Qiao, Naveen Garg, Cristhiam M. Rojas-Hernandez
Summary: This study retrospectively reviewed the treatment of cerebral venous thrombosis in 45 cancer patients, finding recanalization in nearly 60% of cases, a recurrence or propagation rate of 15.6% at 12 months, and major bleeding complications in 15 patients. The findings suggest a narrow therapeutic index of anticoagulation in cancer patients with CVT, highlighting the importance of careful monitoring for anticoagulation effect and bleeding complications. Further larger and controlled studies are needed to validate these observations.
THROMBOSIS JOURNAL
(2021)
Article
Oncology
Norman Brito-Dellan, Nikolaos Tsoukalas, Carme Font
Summary: Cancer and COVID-19 have similarities in terms of thrombosis, D-dimer levels, and the failure of anticoagulation therapy. Cancer patients are more vulnerable to COVID-19 and have a higher mortality rate. Managing cancer-associated thrombosis in COVID-19 patients requires special considerations. Cancer patients should be given priority for COVID-19 vaccination, although they may have a weaker immune response. Additional doses and booster shots of the COVID-19 vaccine are recommended for patients undergoing active cancer treatment.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Cardiac & Cardiovascular Systems
Christophe Vandenbriele, Deepa J. Arachchillage, Pascal Frederiks, Gennaro Giustino, Diana A. Gorog, Mario Gramegna, Stefan Janssens, Bart Meyns, Amin Polzin, Mara Scandroglio, Benedikt Schrage, Gregg W. Stone, Guido Tavazzi, Thomas Vanassche, Pascal Vranckx, Dirk Westermann, Susanna Price, Alaide Chieffo
Summary: There is growing interest in the use of mechanical circulatory support for patients with cardiogenic shock, but the delicate balance between bleeding and thrombosis poses challenges for patient outcomes. This article presents an anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algorithm and discusses the monitoring pitfalls of heparin in critically ill patients, aiming to guide physicians in standardizing anticoagulation treatment to reduce device-related morbidity and mortality.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Hematology
Katrina Piedra, Tim Peterson, Carlyn Tan, Jennifer Orozco, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Alexander Lesokhin, Urvi Shah, Sydney Lu, Dhwani Patel, Andriy Derkach, Cy R. Wilkins, Neha Korde
Summary: The incidence of venous thromboembolism varies across different regimens in newly diagnosed multiple myeloma patients, with higher rates seen in those treated with KRD induction. The use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Sergio Raposeiras Roubin, Emad Abu Assi, Isabel Munoz Pousa, Pablo Dominguez Erquicia, Maria Melendo Viu, Inmaculada Gonzalez Bermudez, Andres Iniguez Romo
Summary: This study aimed to assess the incidence and predictors of bleeding in patients with atrial fibrillation (AF) and cancer. It found a significant association between cancer and bleeding in patients with AF, particularly in those with active cancer or previous radiotherapy. Age, gender, diabetes, and anticoagulation were identified as independent predictors of bleeding, with vitamin K antagonist anticoagulation associated with bleeding. Existing bleeding risk scores had poor predictive ability in this population.
AMERICAN JOURNAL OF CARDIOLOGY
(2022)
Review
Oncology
Marta Masini, Matteo Toma, Paolo Spallarossa, Italo Porto, Pietro Ameri
Summary: RCTs have demonstrated that rivaroxaban, edoxaban, and apixaban are equally effective as LMWH in treating CAT, but increase the risk of major gastrointestinal bleeding. Apixaban and rivaroxaban can also prevent CAT in high-risk chemotherapy patients, but may lead to higher bleeding likelihood. Limited data is available for using DOAC in individuals with intracranial tumors or thrombocytopenia, and drug interactions with anticancer agents may affect DOAC effectiveness-safety profile. Current guidelines recommend DOAC as the first-line anticoagulants for CAT, but caution should be exercised in specific patient subgroups.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Critical Care Medicine
Warren Clements, Elissa Marshall, Matthew Lukies, Tim Joseph, Huyen Tran, Ee Jun Ban, Jim Koukounaras
Summary: This retrospective study found that the presence of prophylactic IVC filters did not result in the development of caval thrombosis, regardless of whether therapeutic anticoagulation was prescribed or not. The decision to use anticoagulation during IVC filter dwell should be based on the presence of a related thrombosis event rather than the presence of the IVC filter alone.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
(2022)
Article
Medicine, General & Internal
Alessandro Squizzato, Silvia Galliazzo, Elena Rancan, Marina Di Pilla, Giorgia Micucci, Gianmarco Podda, Emanuele Valeriani, Leonardo Campiotti, Lorenza Bertu, Walter Ageno, Ettore Porreca, Corrado Lodigiani
Summary: The optimal management of venous thromboembolism (VTE) in cancer patients with thrombocytopenia remains uncertain. The study found that different therapeutic strategies were associated with varying degrees of thrombocytopenia, and individualized anticoagulation strategies should be tailored based on the patient's platelet count, VTE presentation, and the presence of cerebral metastasis.
INTERNAL AND EMERGENCY MEDICINE
(2022)
Article
Hematology
Jecko Thachil, Alok Khorana, Marc Carrier
Summary: COVID-19 and cancer continue to pose significant challenges in healthcare, with both conditions sharing similarities such as high rates of thrombosis and marked elevation of D-dimers. Hemostasis and thrombosis specialists need to study these similarities and provide insights for future research and therapeutic trials.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Oncology
Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem
Summary: Adding napabucasin to paclitaxel did not improve survival in patients with second-line advanced gastric or gastroesophageal junction adenocarcinoma. The safety profile of napabucasin was driven by manageable gastrointestinal events, with grade >= 3 diarrhea occurring at a higher frequency with napabucasin plus paclitaxel versus placebo plus paclitaxel.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Manish A. Shah, Anghel Adrian Udrea, Igor Bondarenko, Was Mansoor, Raquel Guardeno Sanchez, Tomasz Sarosiek, Silvia Bozzarelli, Michael Schenker, Carlos Gomez-Martin, Carys Morgan, Mustafa oezgueroglu, Joanna Pikiel, Haralabos P. Kalofonos, Elzbieta Wojcik, Tomas Buchler, Daniel Swinson, Irfan Cicin, Mano Joseph, Ihor Vynnychenko, Alexander Valerievich Luft, Peter C. Enzinger, Tomas Salek, Christos Papandreou, Christophe Tournigand, Evaristo Maiello, Ran Wei, David Ferry, Ling Gao, Joana M. Oliveira, Jaffer A. Ajani
Summary: Ramucirumab at a dosage of 8 mg/kg every 2 weeks is a standard treatment option for second-line advanced/metastatic gastric/gastroesophageal junction adenocarcinoma, either as monotherapy or in combination with paclitaxel. Different dosing regimens were explored in these studies, but there was no dose/exposure-response relationship supporting the use of the standard dose of ramucirumab.
Article
Oncology
Manish A. Shah, Takashi Kojima, Daniel Hochhauser, Peter Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung-Bae Kim, Masahiro Tajika, Albert Craig Lockhart, Hendrick-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Pooja Bhagia, Zhu Alexander Cao, Jared Lunceford, Shailaja Suryawanshi, Mark Ayers, Matthew J. Marton, Ken Kato
Summary: This study found that the 18-gene T cell-inflamed gene expression profile (Tcell(inf)GEP) and PD-L1 combined positive score (CPS) may enrich for responders to pembrolizumab in patients with esophageal cancer.
Article
Cell Biology
Anna Morena D'Alise, Nadia Brasu, Carlo De Intinis, Guido Leoni, Valentina Russo, Francesca Langone, Denis Baev, Elisa Micarelli, Luca Petiti, Simone Picelli, Marwan Fakih, Dung T. Le, Michael J. Overman, Anthony F. Shields, Katrina S. Pedersen, Manish A. Shah, Sarbajit Mukherjee, Thea Faivre, Patricia Delaite, Elisa Scarselli, Luigia Pace
Summary: Targeting tumor neoepitopes with gorilla adenovirus (Ad) vaccines can enhance antitumor immune response and improve immunogenicity when combined with anti-PD-1 therapy. The combination treatment increases the number of polyfunctional neoantigen-specific CD8(+) T cells and enhances the infiltration of immune cells in tumors.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Josep Tabernero, Paulo M. Hoff, Lin Shen, Atsushi Ohtsu, Manish A. Shah, Asna Siddiqui, Sarah Heeson, Astrid Kiermaier, Harrison Macharia, Eleonora Restuccia, Yoon-Koo Kang
Summary: This study aimed to evaluate the long-term efficacy and safety of pertuzumab plus trastuzumab and chemotherapy in previously untreated HER2-positive metastatic gastric or gastroesophageal junction cancer. The results showed increased overall survival and progression-free survival, higher objective response rate, and comparable safety in the pertuzumab arm.
Editorial Material
Health Care Sciences & Services
Rutika Mehta, Manish A. Shah
ANNALS OF PALLIATIVE MEDICINE
(2022)
Article
Oncology
Manish A. Shah, Takayuki Yoshino, Niall C. Tebbutt, Axel Grothey, Josep Tabernero, Rui-Hua Xu, Andres Cervantes, Sang Cheul Oh, Kensei Yamaguchi, Marwan Fakih, Alfredo Falcone, Christina Wu, Vi K. Chiu, Jiri Tomasek, Johanna Bendell, Marilyn Fontaine, Matthew Hitron, Bo Xu, Julien Taieb, Eric Van Cutsem
Summary: In this study, patients with colorectal cancer were divided into two groups, one receiving combination therapy of napabucasin and FOLFIRI, and the other receiving FOLFIRI alone. The results showed that the addition of napabucasin to FOLFIRI did not significantly improve overall survival compared to the control group.
CLINICAL COLORECTAL CANCER
(2023)
Article
Oncology
Manish A. Shah, Erin B. Kennedy, Ashley E. Alarcon-Rozas, Thierry Alcindor, Angela N. Bartley, Aubrey Belk Malowany, Nishin A. Bhadkamkar, Dana C. Deighton, Yelena Janjigian, Asha Karippot, Uqba Khan, Daniel A. King, Kelsey Klute, Jill Lacy, James J. Lee, Rutika Mehta, Sarbajit Mukherjee, Arun Nagarajan, Haeseong Park, Anwaar Saeed, Thomas J. Semrad, Kohei Shitara, Elizabeth Smyth, Nataliya Uboha, Melani Vincelli, Zev Wainberg, Lakshmi Rajdev
Summary: The purpose of this study is to develop recommendations for targeted therapies in advanced gastroesophageal cancer. A systematic review was conducted, and 18 randomized controlled trials were included. The recommendations include first-line therapy with nivolumab and chemotherapy for HER2-negative patients with gastric adenocarcinoma and PD-L1 CPS >= 5, and pembrolizumab and chemotherapy for HER2-negative patients with esophageal or gastroesophageal junction AC and PD-L1 CPS >= 10. Clinical trials are recommended as targeted treatment options for gastroesophageal cancer are expected to evolve.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Walid K. Chatila, Henry Walch, Jaclyn F. Hechtman, Sydney M. Moyer, Valeria Sgambati, David M. Faleck, Amitabh Srivastava, Laura Tang, Jamal Benhamida, Dorina Ismailgeci, Carl Campos, Fan Wu, Qing Chang, Efsevia Vakiani, Elisa de Stanchina, Martin R. Weiser, Maria Widmar, Rhonda K. Yantiss, Manish A. Shah, Adam J. Bass, Zsofia K. Stadler, Lior H. Katz, Ingo K. Mellinghoff, Nilay S. Sethi, Nikolaus Schultz, Karuna Ganesh, David Kelsen, Rona Yaeger
Summary: Inflammation is recognized as a contributing factor to cancer development, particularly in the gastrointestinal tract. In this study, the clinical features, genomic landscape, and germline alterations of colitis-associated cancers were defined. TP53 alterations were a common event in colitis-associated cancers, occurring in half of dysplasia, while Wnt pathway alterations were infrequent. The sequencing results from multiple dysplasia/cancer lesions suggest that these lesions largely occur as genetically independent events with lineage plasticity away from Wnt activation.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Olivia Fankuchen, Jennifer Lau, Mangala Rajan, Brandon Swed, Peter Martin, Manuel Hidalgo, Samuel Yamshon, Laura Pinheiro, Manish A. Shah
Summary: This study examined the long-term effects of COVID-19 infection in cancer patients and found that cancer patients had higher mortality rates after hospital discharge. Additionally, approximately one-third of all patients experienced long COVID symptoms.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2023)
Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Review
Oncology
Manish A. Shah, Nasser Altorki, Pretish Patel, Sebron Harrison, Adam Bass, Julian A. Abrams
Summary: Oesophageal cancer is a common malignancy with significant morbidity and mortality. Advances in disease understanding, screening, monitoring technologies, surgical techniques, radiotherapy, and systemic therapy have improved patient outcomes. The development of minimally invasive diagnostic technologies based on cancer-specific genomic or epigenetic alterations has the potential to enhance screening. Less invasive surgical techniques and immune-checkpoint inhibitors also hold promise in improving treatment. This review discusses these advances and highlights the ongoing transformation in oesophageal cancer management.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Lakshmi Rajdev, Erin B. Kennedy, Manish A. Shah
JCO ONCOLOGY PRACTICE
(2023)
Article
Biochemistry & Molecular Biology
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu
Summary: The GLOW trial demonstrated that zolbetuximab, a monoclonal antibody targeting CLDN18.2, combined with CAPOX, significantly improved progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Article
Oncology
Jung Eun Baik, Li Li, Manish A. Shah, Daniel E. Freedberg, Zhezhen Jin, Timothy C. Wang, Yiping W. Han
Summary: Fusobacterium nucleatum (Fn) is a common gram-negative anaerobic bacterium that promotes colorectal cancer development through the secretion of FadAc. This study found that circulating levels of anti-FadAc IgA were significantly increased in patients with colorectal cancer, particularly in those with proximal tumors. Therefore, anti-FadAc IgA may serve as a serological biomarker for early detection of colorectal cancer.
CANCER RESEARCH COMMUNICATIONS
(2022)
